• C M Lowry, F M Marty, S O Vargas, J T Lee, K Fiumara, A Deykin, and L R Baden.
• Department of Pharmacy, Brigham & Women's Hospital, Boston, MA 02115, USA.
• Transpl Infect Dis. 2007 Jun 1; 9 (2): 121-5.

BackgroundNebulized amphotericin B deoxycholate (AmBd) has been used to prevent invasive pulmonary aspergillosis after lung transplantation.MethodsIn this retrospective study we compared the safety and tolerability of nebulized AmBd and nebulized liposomal amphotericin B (L-AmB) in 38 consecutive lung transplant recipients. Progress notes, medication administration records, microbiology, and pulmonary function reports were reviewed. Histologic sections from lung tissue were examined. Plasma amphotericin B levels were measured.ResultsA total of 1206 doses of AmBd and 1149 doses of L-AmB were administered. Eighteen patients received AmBd only, 11 received L-AmB only, and 9 received the medications sequentially. The total number of complaints vs. the number of doses administered was 1.0% for AmBd-treated patients and 1.2% for L-AmB-treated patients. No differences were observed between the treatment groups on lung biopsy specimens. Plasma amphotericin B levels were <0.2-0.9 microg/mL in AmBd-treated patients and <0.2 microg/mL in L-AmB-treated patients.ConclusionsIn lung transplant recipients, both inhaled AmBd and L-AmB were safe and well tolerated over a large number of medication exposures.

25 keywords...

hide…